Here is the design of a clinical trial:

Official Title: Cannabidiol in Children With Refractory Epileptic Encephalopathy: A Phase 1 Open Label Dose Escalation Study (CARE-E)

Included conditions:
- Epileptic Encephalopathy

Study Armgroups:
- {'label': 'Medical Cannabis Oil', 'type': 'EXPERIMENTAL', 'description': 'CanniMed® 1:20', 'interventionNames': ['Drug: CanniMed® 1:20']}

Interventions:
- {'type': 'DRUG', 'name': 'CanniMed® 1:20', 'description': 'A cannabidiol (CBD): tetrahydrocannabinol (Δ9 THC) 20:1 ratio product will be provided as an oil-based suspension.', 'armGroupLabels': ['Medical Cannabis Oil'], 'otherNames': ['Medical Cannabis Oil']}

Primary Outcomes:
- {'measure': 'Heart Rate', 'timeFrame': 'Up to 6 months'}
- {'measure': 'Blood Pressure', 'timeFrame': 'Up to 6 months'}
- {'measure': 'Weight', 'timeFrame': 'Up to 6 months'}
- {'measure': 'Complete Blood Count (CBC) and Differential', 'timeFrame': 'Up to 6 months'}
- {'measure': 'Sodium, potassium, chloride, calcium, magnesium, phosphate and carbon dioxide (mmol/L)', 'timeFrame': 'Up to 6 months'}
- {'measure': 'Blood Urea Nitrogen (mmol/L)', 'timeFrame': 'Up to 6 months'}
- {'measure': 'Creatinine (umol/L)', 'timeFrame': 'Up to 6 months'}
- {'measure': 'Aspartate aminotransferase (AST), Alanine aminotransferase (ALT), Alkaline phosphatase (ALP), Gamma-glutamyl transferase (GGT) and Lipase (U/L)', 'timeFrame': 'Up to 6 months'}
- {'measure': 'Total and Direct Bilirubin (umol/L)', 'timeFrame': 'Up to 6 months'}
- {'measure': 'Albumin (g/L)', 'timeFrame': 'Up to 6 months'}
- {'measure': 'Total Cholesterol and Triglyceride (mmol/L)', 'timeFrame': 'Up to 6 months'}
- {'measure': 'Clobazam and Norclobazam Levels (umol/L)', 'description': 'For participants taking clobazam who become excessively sedated', 'timeFrame': 'Up to 6 months'}
- {'measure': 'Clonazepam Level (umol/L)', 'description': 'For participants taking clonazepam who become excessively sedated', 'timeFrame': 'Up to 6 months'}
- {'measure': 'Urine Ketones', 'description': 'For participants on the ketogenic diet', 'timeFrame': 'Up to 6 months'}
- {'measure': 'Trough Level of Concomitant Anti-Convulsants', 'description': 'Measure interactions with any anti-convulsants participants may be already on', 'timeFrame': 'Up to 7 months'}
- {'measure': 'Adverse Events', 'description': 'Side effect rating scale, includes items related to sleepiness/lethargy, irritability, nausea/vomiting and diarrhea', 'timeFrame': 'Through study completion, up to 7 months'}
- {'measure': '2-hour Electroencephalogram (EEG) Recording', 'timeFrame': 'Up to 6 months'}

Please estimate the sample size based on the assumption: 
Not explicitly stated; phase I study focused on safety and tolerability.
Sample size determination
        As CARE-E is a phase I dose escalation safety and tolerability study designed to find the most appropriate dose of CBD in a pediatric population it was felt that power analysis was not required to calculate sample size. The sample size of 28 participants each receiving 4 separate dosage escalations is within usual guidelines for standard phase I clinical trial designs. In this multi-site dose escalation study, we chose to escalate within the same participant with 7 participants at each site because the low pediatric population incidence of epileptic encephalopathy (the inclusion criterion), precluded ability to escalate in cohorts of 6, where a new cohort of six would be administered the next dosing level [20, 21]. Any patient exhibiting a dose limiting toxicity will not receive the next dose escalation.